Navigation Links
EpiCept Releases New Data Demonstrating Prolonged Five-Year Leukemia-Free Survival for AML Patients Treated with Ceplene(TM) + IL-2
Date:12/9/2007

express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on EpiCept's current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risk that Ceplene will not receive regulatory approval or marketing authorization in the EU or that Ceplene, if approved, will not achieve significant commercial success, the risk that our NP-1 clinical trials will not be successful, that NP-1 will not receive regulatory approval or achieve significant commercial success, the risk that Myriad's development of Azixa(TM) will not be successful, the risk that Azixa(TM) will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our agreement with Myriad, the risk that the development of our other apoptosis product candidates will not be successful, the risk that our ASAP technology will not yield any successful product candidates, the risk that clinical trials for EPC 2407 will not be successful, that EPC 2407 will not receive regulatory approval or achieve significant commercial success, the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later stage clinical trials, the risk that EpiCept will not obtain approval to market any of its product candidates, the risks associated with our need to raise additional financing to continue to meet our capital needs and our ability to continue as a going concern, the risks associated with dependence upon key personnel, the risks associated with reliance on collaborative partners an
'/>"/>
SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. EpiCept Corporation to Present at the 2007 BIO InvestorForum
2. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
3. EpiCept Corporation To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. EpiCept To Host Third Quarter 2007 Conference Call and Webcast on November 7, 2007
5. EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results
6. EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference
7. Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
8. EpiCept Announces Presentation of New Ceplene(TM) Data at the 49th Annual Meeting of the American Society of Hematology
9. EpiCept Corporation Announces Pricing of Public Offering
10. EpiCept Corporation to Present at The New York Society of Security Analysts 11th Annual Biotech & Specialty Pharma Conference
11. Cleveland Clinic Press Releases Journal-Writing Book Write for Life: Healing Body, Mind, and Spirit Through Journal Writing by Sheppard B. Kominars, Ph.D.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... (PRWEB) October 02, 2014 USARAD ... teleradiology and telemedicine solutions provider including its SecondOpinions.com® ... Backhaus have joined its Executive Team as President ... , Brent Backhaus, USARAD’s new President and COO, ... years of progressively responsible experience in commercial-, medical- ...
(Date:10/2/2014)... Social-Engineer, Inc. the leader in security testing and ... a complimentary webinar on Friday, October 31, at 1:00PM ... of the annual Social-Engineer Capture the Flag (SECTF) competition ... explore how to maximize security and employee performance to ... the webinar go to: Free Webinar Registration . ...
(Date:10/2/2014)... is a distinguished bamboo product manufacturer and retailer. Plenty ... global customers in the past few years. Now, the ... All its online workers are professional and patient; they ... company has recently added a new assortment of ... marketing specialist has announced that all these brand new ...
(Date:10/2/2014)... may interact with stress to trigger heart disease in some ... in about 13 percent of people, but only in those ... their heart disease risk through simple measures such as ... researchers said. The study authors analyzed genetic data from ... in the EBF1 gene and higher levels of central obesity, ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 (HealthDay News) -- ... may face an increased risk of dying in the next several ... older Americans, researchers found those who were unable to detect scents ... as likely to die in the next five years, versus those ... the inability to distinguish odors -- was a bigger predictor of ...
Breaking Medicine News(10 mins):Health News:Teleradiology and Telemedicine Pioneers Brent Backhaus and Lorna Backhaus Join USARAD Holdings, INC. & SecondOpinions.com® 2Health News:Teleradiology and Telemedicine Pioneers Brent Backhaus and Lorna Backhaus Join USARAD Holdings, INC. & SecondOpinions.com® 3Health News:Social-Engineer, Inc. Announces DEF CON 22 Capture the Flag Results in a Complimentary Webinar 2Health News:Social-Engineer, Inc. Announces DEF CON 22 Capture the Flag Results in a Complimentary Webinar 3Health News:High Quality Bamboo Panels Online At BamboofloorChina.com 2Health News:Genes May Make Some More Prone to Heart Disease When Under Stress 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3
... - Promotes Commercial Products at Major Cardiology Conferences - - ... - Achieves Efficiencies and Conserves Cash by Consolidating R&D ... ... Neovasc Inc. (TSXV: NVC), a,new specialty vascular device company, today reported on ...
... A very difficult-to-treat child leukemia may benefit from the ... launches the cancer but could potentially be reversed ... The study, led by researchers at Children,s Hospital Boston ... in the November 4 issue of Cancer Cell ...
... Rhode Island Hospital researchers have identified genetic proteins, also ... the microscopic level that can signal a precancerous condition ... who are likely to progress to esophageal cancer. This ... journal Clinical Cancer Research . , Barrett,s esophagus ...
... DUBLIN, Calif., Nov 3 SuperGen, Inc. (Nasdaq:,SUPG), ... development,of novel cancer therapies, today announced that James ... scheduled to present at the,Rodman & Renshaw 10th ... the New York Palace Hotel., SuperGen,s presentation ...
... Global Awards Ceremony Featuring Performances by Grammy Award ... Country Music Star Kenny Rogers, OAK BROOK, ... hosted its 24th Annual Awards of Excellence,celebration on ... who have made outstanding contributions to improve the ...
... CONCORD, Mass., Nov. 3 The Melanoma,Foundation of ... to its fall symposium: "Updates in Melanoma Treatment",presented ... Melanoma Program at Dana,Farber Cancer Institute. A portion ... "Immunotherapy: A Panel Presentation," which includes a panel ...
Cached Medicine News:Health News:Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options 2Health News:Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options 3Health News:Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options 4Health News:Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options 5Health News:Tackling a hard-to-treat childhood cancer by targeting epigenetic changes 2Health News:New research finds markers for esophageal cancer before it develops 2Health News:Ronald McDonald House Charities(R) Awards of Excellence Honors Peter and Virginia Ueberroth, Dr. Catherine D. Deangelis and Lionel Whitehead 2Health News:Ronald McDonald House Charities(R) Awards of Excellence Honors Peter and Virginia Ueberroth, Dr. Catherine D. Deangelis and Lionel Whitehead 3
(Date:10/2/2014)... 2, 2014  InfinityQS International, Inc., the global ... announces key client speakers for Infusion Chicago, its ... The event will be held Oct. 9-10, 2014, ... include projects from Coloplast, The Kellogg Company, Biomet, ... King. The two-day event will also include best ...
(Date:10/2/2014)...  AxelaCare Health Solutions, www.axelacare.com , a leading ... it has acquired Advanced Care, a New ... of the transaction were not disclosed. The ... to 18 nationwide and expands AxelaCare,s national home IV ... - New Jersey metro area.  AxelaCare ...
(Date:10/2/2014)...   Intarcia Therapeutics, Inc. today announced successful ... clinical trials for ITCA 650 (exenatide, delivered continuously once ... The first trial, FREEDOM-1, was a placebo-controlled, double-blind phase ... of ITCA 650 in patients with type 2 diabetes ... significantly superior to placebo for both 40 mcg and ...
Breaking Medicine Technology:InfinityQS Infusion Chicago to Spotlight Manufacturers' Key Successes in Achieving Enterprise Quality 2InfinityQS Infusion Chicago to Spotlight Manufacturers' Key Successes in Achieving Enterprise Quality 3AxelaCare Health Solutions Acquires Advanced Care of New York 2AxelaCare Health Solutions Acquires Advanced Care of New York 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5
... Health Inc, Morrisville, NC has introduced IronUp, a Liquid ... dietary iron for infants and children who do not ... (Photo: http://photos.prnewswire.com/prnh/20110810/CL49882 ) ... supplement from a bioavailable source of iron that is ...
... 9, 2011 Q2 2011 Highlights (compared to ... 9% to $109.6 million Product revenue rose 17% to $102.6 ... 2% to 37,300 Masimo rainbow revenue rose 26% to $9.1 ... prior period, which included $0.01 in one-time expenses.  Excluding the prior ...
Cached Medicine Technology:YASOO Health Introduces IronUp™ 2Masimo Reports Second Quarter 2011 Financial Results 2Masimo Reports Second Quarter 2011 Financial Results 3Masimo Reports Second Quarter 2011 Financial Results 4Masimo Reports Second Quarter 2011 Financial Results 5Masimo Reports Second Quarter 2011 Financial Results 6Masimo Reports Second Quarter 2011 Financial Results 7Masimo Reports Second Quarter 2011 Financial Results 8
IVUS console...
FemoStop system is a femoral compression system for hemostasis management. It provides a comfortable and efficient "hands off method of compressing the femoral artery and vein after diagnostic and i...
VasoSeal ES is a extravascular arterial sealing. It utilizes a unique temporary arterial locator system which provides an easier and surer method of locating the femoral artery....
... was the first device ... after diagnostic and interventional ... It is a collagen-based ... for immediate sheath removal ...
Medicine Products: